TABLE 1.
Editor | ssODN | Target Mutation | PAM Mutation | No. of Blastocysts | HDR + ve | 100% HDR |
---|---|---|---|---|---|---|
gRNA 129F/Cas9 | 1288 | PMEL: ΔCTT (p.Leu18del) | No | 64 | 55/64 (86%) a | 6/64 (9%) a |
TALEN TL17/TR217 | 1288 | PMEL: ΔCTT (p.Leu18del) | NA | 66 | 68/69 (99%) b | 33/69 (48%) b |
gRNA 632/Cas9 | 1403 | PRLR: T > A (p.C440*) | Yes | 49 | 22/49 (45%) a | 3/49 (6%) a |
gRNA 634/Cas9 | 1446 | PRLR: ΔC (p.L462*) | Yes | 25 | 7/25 (28%) a | 1/25 (4%) ab |
gRNA 634/Cas9 | 1411 | PRLR: ΔC, C > A (p.L462*, p.S465*) | Yes | 151 | 96/151 (64%) b | 0/151 (0%) b |
gRNA 631/Cas9 | 1344 | PRLR: ΔC (p.L462*) | Yes | 7 | 4/7 (57%) ab | 0/7 (0%) ab |
abValues for PMEL, and PRLR, editing with different superscripts within a column differ p < 0.01.